620112-78-9

中文名称 ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈

英文名称 alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile

CAS 620112-78-9

分子式 C26H18N4O2S

分子量 450.51

MOL 文件 620112-78-9.mol

更新日期 2025/05/22 15:25:50

620112-78-9 结构式

基本信息物理化学性质安全数据 ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈价格(试剂级) 常见问题列表

基本信息

中文别名

RGS抑制剂(CCG-63802)
ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈

英文别名

CCG-63802
CCG 63802
CCG63802
(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)a
(E)-2-(Benzo[d]thiazol-2-yl)-3-(9-methyl-4-oxo-2-(m-tolyloxy)-4H-pyrido[1,2-a]pyrimidin-3-yl)acry
α-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile
2-Benzothiazoleacetonitrile, α-[[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-
alpha-[[9-Methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]methylene]-2-benzothiazoleacetonitrile
(2E)-2-(1,3-Benzothiazol-2-yl)-3-[9-methyl-2-(3-methylphenoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]acrylonitrile

物理化学性质

沸点547.9±60.0 °C(Predicted)

密度1.31

储存条件Sealed in dry,Store in freezer, under -20°C

溶解度Limited solubility, soluble in DMSO

酸度系数(pKa)-0.42±0.70(Predicted)

形态固体

颜色黄色

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS07

警示词警告

危险性描述H302-H315-H319-H335

防范说明P261-P305+P351+P338

危险品标志T

危险类别码25

安全说明45

ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/05/22	HY-70074	ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 CCG-63802	620112-78-9	5mg	660元
2025/05/22	HY-70074	ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 CCG-63802	620112-78-9	10mg	1100元
2025/05/22	HY-70074	ALPHA-[[9-甲基-2-(3-甲基苯氧基)-4-氧代-4H-吡啶并[1,2-A]嘧啶-3-基]亚甲基]-2-苯并噻唑乙腈 CCG-63802	620112-78-9	50mg	3520元

常见问题列表

生物活性

CCG-63802 是一种选择性，可逆变构的 G 蛋白信号调节子 RGS4 抑制剂。CCG-63802 与 RGS4 特异性结合并阻断 RGS4-Gαo 相互作用，IC50 值为 1.9 μM。

靶点

RGS4

1.9 μM (IC ₅₀ )

体外研究

CCG-63802 (5 μM) inhibits regulators of G-protein signaling (RGS) proteins in the presence of BK (bradykinin) and 8-Br-cGMP (membrane-permeable analogue of cGMP), HEK-293 cells start to depolarize again.

体内研究

CCG-63802 (0.05 mg/kg; intratracheal administration; once per week; 90 days) reduces RGS4 protein expression, leading to partially abrogate the attenuating effect of PGZ on airway inflammation, hyperresponsiveness (AHR), and remodeling.

Animal Model:	Forty female BALB/c mice aged 6-8 week old
Dosage:	0.05 mg/kg
Administration:	Intratracheal administration; once per week; 90 days
Result:	CCG 63802 treatment in OVA +PGZ + CCG group significantly reduced RGS4 protein expression compared to OVA + PGZ group (P < 0.05)